Skip to content

Using Rectal Hydrogel Spacer for Salvage SABR in Prostate Cancer

Prostate Cancer

There are several single institutional series that have reported their experience with salvage radiotherapy options that include EBRT, LDR and HDR brachytherapy. Gastrointestinal (GI) toxicity with salvage radiotherapy range between14-58%, respectively for patients undergoing re-irradiation. There is a concern for an increased risk of fistula development in these patients who receive second course of radiation. Hypofractionation using SABR has been utilized in the re-irradiation setting for prostate cancer with good tumor control and toxicity outcomes. In order to decrease the rectal toxicity, dose to the rectum should be kept as low as possible. Several techniques can be used to achieve this: tighter dosimetric dose painting, better patient or organ immobilization or use of a biodegradable gel. The Investigators ropose a phase I study to assess placement of a hydrogel spacer between the prostate and rectum, in an effort to decrease toxicity and improve patient's bowel quality of life.

null

Participation Requirements

  • Sex:

    MALE

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Histologically and radiologically confirmed locally recurrent prostate adenocarcinoma
* Willing to give informed consent to participate in this clinical trial
* Able and willing to complete EPIC and EQ-5D questionnaires

Exclusion Criteria:

* Contraindication to prostate MRI
* Anticoagulation medication (if unsafe to discontinue)
* Diagnosis of bleeding diathesis
* Poor baseline urinary function defined as International Prostate Symptom Score (IPSS) \>20
* Evidence of castrate resistance (defined as PSA \> 3 ng/ml while testosterone is \< 0.7nmol/l). Patients could have been on combined androgen blockade but are excluded if this was started due to PSA progression.
* Definitive extrapelvic nodal or distant metastatic disease on staging investigations.
* Prior ultra-hypofractionated radiotherapy ( SBRT of 5Gy/fraction or higher)

Study Location

Sunnybrook Odette Cancer Centre
Sunnybrook Odette Cancer Centre
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Amandeep Taggar, MD

416 480 6165
Study Sponsored By
Sunnybrook Health Sciences Centre
Participants Required
More Information
Study ID: NCT05597852